Preparation of controlled degradation of insulin-like growth factor 1/spider silk protein nanofibrous membrane and its effect on endothelial progenitor cell viability

Bioengineered. 2021 Dec;12(1):8031-8042. doi: 10.1080/21655979.2021.1982270.

Abstract

The present study aimed to prepare a kind of controlled-releasing insulin-like growth factor 1 (IGF-1)/spider silk protein nanofibrous membrane using a electrostatic spinning method and evaluated its effect on the cell viability of endothelial progenitor cells (EPCs). Recombinant spidroin named as GMCDRSSP-IgF-1 was electro-spun into nanofibrous membrane which can be degraded by protease and be capable of sustained-release of IGF-1. The membrane can be degraded after being treated with thrombin. The release assay results showed that IGF-1 concentration could be maintained at 20 ng/ml for a long time with treatment of Tobacco Etch Virus (TEV) protease. The viability of EPCs on GMCDRSSP-IgF-1 nanofibrous membrane was significantly increased with the presence of TEV protease. The controlled and sustained release of IGF-1 from the nanofibrous membrane could promote the adhesion and viability of EPCs. In summary, the nanofibrous membrane that exhibits controlled degradation and sustained release of IGF-1 was prepared with electrostatic spinning from genetically modified recombinant spider silk protein. The nanofibrous membrane exhibited good blood compatibility and cytocompatibility. With the presence of TEV protease, the sustained-release of IGF-1 significantly promoted the adhesion and viability of EPCs. The new nanofibrous membrane can be potentially used as a scaffold for EPCs culture in vitro and future in vivo studies.

Keywords: Controlled-releasing; IGF-1; TEV protease; degradation; endothelial progenitor cells; nanofibrous membrane.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Adhesion / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cysteine Endopeptidases / metabolism
  • Delayed-Action Preparations
  • Endothelial Progenitor Cells / cytology*
  • Fibroins / genetics*
  • Fibroins / metabolism
  • Humans
  • Insulin-Like Growth Factor I / genetics*
  • Insulin-Like Growth Factor I / metabolism
  • Insulin-Like Growth Factor I / pharmacology*
  • Recombinant Proteins / pharmacology
  • Static Electricity
  • Tissue Engineering
  • Tissue Scaffolds / chemistry

Substances

  • Delayed-Action Preparations
  • Recombinant Proteins
  • Insulin-Like Growth Factor I
  • Fibroins
  • Cysteine Endopeptidases
  • Ulp1 protease

Grants and funding

This study was supported by the China Postdoctoral Science Foundation (Nos. 2018M631048 and 2019T120792), the National Natural Science Foundation of China (Nos. 81700263 and 81660591), the Guangdong Basic and Applied Basic Research Foundation (Nos. 2019A1515010329 and 2021A1515010178). The Natural Science Foundation of Jiangxi Province (Nos. 20171BAB215070 and 20171BAB215067), the Science and Technology Program of Health Commission of Jiangxi Province (No. 20191053).